Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CPO107 |
Trade Name | |
Synonyms | CPO 107|CPO-107|JMT601 |
Drug Descriptions |
CPO107 is a bispecific fusion protein consisting ofatumumab, an anti-CD20 antibody, linked to signal regulatory protein alpha (SIRPalpha), which targets CD20 and CD47 expressed on tumor cells, potentially leading to antibody-dependent and complement-mediated tumor cell cytotoxicity and increased tumor cell phagocytosis and anti-tumor T-cell response (NCI Drug Dictionary). |
DrugClasses | CD20 Antibody 25 CD47 Antibody 31 |
CAS Registry Number | NA |
NCIT ID | C179727 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CPO107 | CPO107 | 0 | 1 |